Related references
Note: Only part of the references are listed.Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)
Christopher A. Yasenchak et al.
BLOOD (2022)
Hypereosinophilic syndromes-An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment
Grzegorz Helbig et al.
BLOOD REVIEWS (2021)
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma
Andrew M. Evens et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Central nervous system involvement of hypereosinophilic syndrome: A report of 10 cases and a literature review
Dokyung Lee et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence
Martin M. Crane et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Hypereosinophilic Syndrome and Clonal Eosinophilia: Point-of-Care Diagnostic Algorithm and Treatment Update
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2010)
CNS involvement in Hodgkin's lymphoma
Daniel Re et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
